
    
      This is a retrospective chart review and prospective observational study. Patients will be
      considered for enrollment if they are receiving BSC and have already decided independently of
      this study not to pursue further therapeutic treatment of their cancer. Patients must have
      received at least two prior treatments for their disease, such as chemotherapy, targeted
      therapy or other regimens.

      The study will consist of administration of informed consent, which will include permission
      to review medical records and record relevant medical information, agreement to be followed
      for survival, and evaluation of the appropriate inclusion/exclusion entry criteria.

      Patients will not have any study-specific assessments performed as part of this study, and
      will be followed only for survival.

      Approximately 80 patients with treatment-resistant, metastatic colorectal cancer who are only
      receiving BSC, will be entered in the study at no more than five sites in the United States
    
  